A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma
What is the purpose of this trial?
This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-636, an oral Dihydroorotate Dehydrogenase (DHODH) inhibitor, in subjects with advanced lymphoma.
- Trial withAgios Pharmaceuticals
- Start Date03/23/2019
- End Date02/21/2022
- Last Updated05/19/2019
- Study HIC#2000024525